FY2024 EPS Estimates for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Raised by Analyst

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) – Equities research analysts at Cantor Fitzgerald raised their FY2024 earnings per share (EPS) estimates for shares of Regeneron Pharmaceuticals in a report released on Monday, April 22nd. Cantor Fitzgerald analyst O. Brayer now expects that the biopharmaceutical company will post earnings of $37.72 per share for the year, up from their previous forecast of $37.66. Cantor Fitzgerald currently has a “Neutral” rating and a $925.00 target price on the stock. The consensus estimate for Regeneron Pharmaceuticals’ current full-year earnings is $38.80 per share.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, topping analysts’ consensus estimates of $10.73 by $1.13. The company had revenue of $3.43 billion for the quarter, compared to the consensus estimate of $3.29 billion. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. Regeneron Pharmaceuticals’s quarterly revenue was up .6% compared to the same quarter last year. During the same period in the previous year, the business earned $10.96 earnings per share.

REGN has been the topic of several other reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $1,189.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 9th. Truist Financial reiterated a “buy” rating and set a $1,135.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 3rd. UBS Group boosted their price target on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a report on Wednesday, April 17th. Bank of America increased their price objective on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research note on Friday, April 12th. Finally, Barclays boosted their target price on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an “overweight” rating in a research note on Tuesday, January 23rd. One analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $976.41.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $900.16 on Tuesday. The company has a current ratio of 5.69, a quick ratio of 4.94 and a debt-to-equity ratio of 0.10. The company’s 50-day moving average price is $952.07 and its 200 day moving average price is $892.70. Regeneron Pharmaceuticals has a 52 week low of $684.80 and a 52 week high of $998.33. The stock has a market cap of $98.80 billion, a price-to-earnings ratio of 25.90, a PEG ratio of 2.58 and a beta of 0.11.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $982.05, for a total value of $98,205.00. Following the transaction, the director now directly owns 18,282 shares of the company’s stock, valued at $17,953,838.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, EVP Marion Mccourt sold 358 shares of the company’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $967.50, for a total value of $346,365.00. Following the completion of the transaction, the executive vice president now directly owns 13,431 shares in the company, valued at $12,994,492.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $982.05, for a total transaction of $98,205.00. Following the sale, the director now directly owns 18,282 shares of the company’s stock, valued at $17,953,838.10. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 11,022 shares of company stock worth $10,552,991. 8.83% of the stock is currently owned by corporate insiders.

Institutional Trading of Regeneron Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Annis Gardner Whiting Capital Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at approximately $26,000. West Paces Advisors Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 575.0% during the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 23 shares during the period. Fortitude Family Office LLC bought a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth about $31,000. MCF Advisors LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 12 shares during the period. Finally, Criterion Capital Advisors LLC acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter worth about $37,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.